Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

TRAIL-R2 polyclonal antibody

ALX-210-743-C200 200 µg 467.00 USD
Do you need bulk/larger quantities?

Product Details

Alternative Name:TRAIL receptor 2, DR5, Death receptor 5, KILLER, CD262, Trick2, Ly98, TNFRSF10B, TNF-related apoptosis-inducing ligand receptor 2, Tumor necrosis factor receptor superfamily member 10B
Immunogen:Synthetic peptide corresponding to aa 68-94 (A68PQQKRSSPSEGL
CPPGHHISEDGRDC94) of the extracellular domain of human TRAIL-R2.
UniProt ID:O14763
Gene/Protein Identifier:8795 (Entrez GeneID)
Species reactivity:Human, Mouse
Applications:Flow Cytometry, ICC, IHC (PS), WB
Recommended Dilutions/Conditions:Immunocytochemistry (1:300)
Immunohistochemistry (paraffin sections)
Western Blot (1:1,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
Application Notes:Detects a band of ~52kDa by Western blot.
Cited applications include Immunoprecipitation.
Purity Detail:Epitope-affinity purified IgG.
Quality Control:Western Blot or Immunocytochemistry on cell lines HEK 293 or Jurkat.
Formulation:Liquid. In PBS containing 1mg/ml BSA and 0.1% sodium azide.
Handling:For maximum product recovery after thawing, centrifuge the vial before opening the cap. Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
Shipping:Blue Ice
Short Term Storage:+4°C
Long Term Storage:-20°C
Regulatory Status:RUO - Research Use Only
TRAIL-R2 polyclonal antibody WB
Figure: Specificity of PAb to TRAIL-R2. Lane 1: TRAIL-R3:Fc. Lane 2: TRAIL-R2. ALX-210-743 recognizes a band of approx. 46kDa of the expected size of the recombinant TRAIL-R2:Fc protein in lane 2 and shows no detectable cross-reactivity to TRAIL-R3:Fc in lane 1."
Please mouse over
TRAIL-R2 polyclonal antibody WB

Product Literature References

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL: A. Meijer, et al.; Br. J. Cancer 109, 2685 (2013), Abstract; Full Text
Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells: J.J. Chen, et al.; Oncotarget 3, 833 (2012), Abstract; Full Text
Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer: B. Yoldas, et al.; Head Neck 33, 1278 (2011), Abstract;
Death receptor 5 signaling promotes hepatocyte lipoapoptosis: S.C. Cazanave, et al.; J. Biol. Chem. 286, 39336 (2011), Application(s): Used for IP and ICC, Abstract;
Effects of androgen ablation therapy in TRAIL death ligand and its receptors expression in advanced prostate cancer: I.T. Koksal, et al.; Urol. Int. 84, 445 (2010), Abstract;
Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis: O. Kutlu, et al.; Int. Urol. Nephrol. 42, 393 (2010), Abstract;
Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma: K.H. Lee, et al.; Langenbecks Arch. Surg. 394, 661 (2009), Abstract;
High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas: A.D. Sanlioglu, et al.; Pancreas 36, 385 (2008), Abstract; Full Text
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas: V. Granci, et al.; Eur. J. Cancer 44, 2312 (2008), Abstract;
Differential expression of TRAIL and its receptors in benign and malignant prostate tissues: A.D. Sanlioglu, et al.; J. Urol. 177, 359 (2007), Abstract;
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity: H. Malhi, et al.; Gut 56, 1124 (2007), Abstract; Full Text
TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma: A.D. Sanlioglu, et al.; Int. J. Radiat. Oncol. Biol. Phys. 69, 716 (2007), Abstract;
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs: T.M. Ganten, et al. ; Cell Death Differ. 11 Suppl 1, S86 (2004), Abstract;
Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5: T.G. Jin, et al.; J. Biol. Chem. 279, 55594 (2004), Abstract; Full Text
Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis: H. Higuchi, et al.; J. Biol. Chem. 278, 454 (2003), Abstract; Full Text
The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis: H. Higuchi, et al.; J. Biol. Chem. 276, 38610 (2001), Abstract; Full Text
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy: A.M. Chinnaiyan, et al.; PNAS 97, 1754 (2000), Abstract; Full Text

General Literature References

Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL: MacFarlane, et al.; J. Biol. Chem. 272, 25417 (1997), Abstract; Full Text
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL: H. Walczak, et al.; EMBO J. 16, 5386 (1997), Abstract; Full Text

Related Products

TRAIL-R2 (human) monoclonal antibody (DJR2-2) 

Flow Cytometry, IHC (PS) | Print as PDF
ALX-804-913-0100 100 µg 262.00 USD
Do you need bulk/larger quantities?

TRAIL-R2 (human) monoclonal antibody (DJR2-4) 

Flow Cytometry | Print as PDF
ALX-804-914-0100 100 µg 262.00 USD
Do you need bulk/larger quantities?

Product Toolbox


Certificate of Analysis


By target:
TRAIL receptor
By biological activity:
TRAIL receptor Polyclonal antibody
By catalog section:


Technical Service
Customer Service